A new approach

What is the clinical need?


Overprescribing and misdiagnosis

  • Most fungal infections are diagnosed by the clinician identifying a set of symptoms

  • Candida infections are often misdiagnosed as bacterial. Similarly, fungal lung infections are often misdiagnosed as TB, in part due to clinicians not trusting tests. This is leading to patients being prescribed the inappropriate treatment18

  • One study reported the unnecessary usage of antifungal medicationsin 16% of cases, the wrong choice of treatment in about one-third of cases and suboptimal treatment in about a half of patients19

  • Without a standardised test, clinicians are potentially missing out on giving antifungal medicine to patients who need it


Traditional diagnostic tests

  • Traditional clinical diagnostic tests can be slow, costly and impractical due to the specialised equipment required to carry out tests16

Cost of care

  • Evidence shows that patients with a fungal infection will cost £50K more per case, compared to someone with a similar underlying disease, but no fungal infection20

  • Drug-resistant infections are a large drain on hospital resources21

  • Cost is often thought of as a barrier to using rapid diagnostics, due to upfront costs. This is short-sighted as rapid diagnostics can reduce costs in the long term due to a reduced incidence of adverse events, decreased use of antifungal treatments and resistance to antifungal treatments18

The lack of a standardised diagnostic approach is leading to empirical or prolonged treatment without a confirmed diagnosis22, increasing harmful resistance to antifungal treatments


A novel diagnostic-led strategy
How to treat fungal infections


The solution to limiting the spread of antifungal resistance?

  • A new rapid diagnostic-led approach will lead to more accurate and timely treatments,23 therefore reducing the spread of resistance, whilst preserving existing medications16,18

This will mean:

  • Infection can be better managed

  • Unnecessary drug prescribing can be avoided

  • Reduced burden on nursing time
    e.g. drug administration and patient monitoring

  • Enhanced patient recovery –
    by applying the right treatment drug at the right dose, at the right time, for the right duration11and patient monitoring16

  • Earlier diagnosis and targeted treatment may also reduce cost burdens, whilst improving patient outcomes24

The solution to reducing costs?

A rapid diagnostic-led approach remains less costly and more effective in preventing death24

  • In one study, total costs were 32% lower for a diagnostic-led strategy versus an empirical approach due to a reduced incidence of adverse events and decreased use of antifungal treatments24

  • It was estimated 41% fewer patients could be treated with antifungal treatments18

Baseline results of costs and outcomes of diagnostic-led and empirical strategies24


  1. Brown GD et al. Sci Transl Med 2012;4(165): 165rv13.
  2. Rüping MJ et al. Drugs 2008;68(14): 1941-62.
  3. Schmiedel Y et al. Swiss Med Wkly 2016;146: w14281.
  4. Wisplinghoff et al. Clin Infect Dis 2004;39: 309-17.
  5. Kollef M et al. Clin Infect Dis 2012;54: 1739-1746.
  6. Hadley S et al. Crit Care Med 2002;30(8): 1808-14.
  7. Leroy O et al. Crit Care Med 2009;37(5): 1612-8.
  8. Guzman JA et al. Clin Med Res 2011;3: 65-71.
  9. Charles PE et al. Intensive Care Med 2003;29(12): 2162-9.
  10. Nolla-Salas J et al. Intensive Care Med 1997;23(1): 23-30.
  11. Bougnoux ME et al. Intensive Care Med 2008;34(2): 292-9.
  12. Alexander BD et al. Clin Infect Dis 2014;58(5): 754.
  13. Biggest Threats - Antibiotic/Antimicrobial Resistance - CDC. Web: https://www.cdc.gov/drugresistance/biggest_threats.html (Last accessed: March 2017).
  14. Kontoyiannis DP et al. Clin Infect Dis 2010;50: 1091-100.
  15. Falcone M et al. Med Mycol 2011;49(4): 406-413.
  16. Fairlamb AH et al. Nat Microbiol 2016;1(7): e16092.
  17. Agrawal S et al. J Antimicrob Chemother 2016;71 Suppl 2: ii37-ii42.
  18. O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. The review on antimicrobial resistance; London: HM Government and the Wellcome Trust; 2016.
  19. Valerio M et al. J Antimicrob Chemother 2014;69: 1993-9.
  20. Ceesay MM et al. J Antimicrob Chemother 2015;70: 1175-1181.
  21. Roberts RR et al. Clin Infect Dis 2009;49(8): 1175-84.
  22. Arendrup MC et al. Bone Marrow Transplant 2012;47: 1030-45.
  23. Arendrup MC et al. Clin Microbial Infect 2014;20 (Suppl. 6): 42-48.
  24. Barnes R et al. Clin Thera 2015;37(6): 1317-1328.e2.
  25. Hoenigl M et al. J Clin Microbiol 2014;52(6): 2039-2045.
  26. White PL et al. J Clin Microbiol 2013;51(5): 1510-1516.
  27. Bassetti M et al. J Antimicrob Chemother 2016;71 (suppl_2): ii13-ii22.
  28. Apisarnthanarak A et al. Infect Control Hosp Epidemiol 2012;31: 722-7.
  29. Standiford HC et al. Infect Control Hosp Epidemiol 2012;33: 338-45.
  30. Leeflang MM et al. Cochrane Database Syst Rev 2008;4: CD0073944.
  31. Cruciani M et al. Cochrane Database Syst Rev 2015;10: CD009551.